Sermorelin: Benefits, Dosage, Side Effects & Where to Get It Prescribed (2026)

Key takeaways

• Sermorelin is a synthetic copy of the first 29 amino acids of growth hormone–releasing hormone (GHRH). It makes your own pituitary release growth hormone in its natural pulses; it is not growth hormone.
• It was FDA-approved for children with growth hormone deficiency (brand Geref), withdrawn in 2008 for commercial reasons, and is now available only as a compounded prescription. It is not on FDA's Category 2 list, which is why licensed pharmacies can still compound it.
• In older adults, studied doses of 1–2 mg a day raised overnight GH output; IGF-1 rose in some trials and not others. Body-composition and strength changes were small. Nobody has shown it extends healthspan.
• Typical telehealth doses (200–500 mcg nightly) are 4–10× lower than the doses used in the published trials. That gap is the most important thing to know before paying for it.
• The most common side effect is an injection-site reaction; flushing, headache and dizziness are less common. The long-term risks are the risks of raising GH and IGF-1: fluid retention, joint pain, insulin resistance, and caution with any active cancer.

Sermorelin at a glance

Also called

GHRH(1-29), sermorelin acetate, GRF 1-29, Geref (discontinued brand)

Class

Growth hormone–releasing hormone (GHRH) analog; a growth hormone secretagogue

Route

Subcutaneous injection, usually once nightly

FDA status

Previously FDA-approved as Geref for pediatric growth hormone deficiency and as a diagnostic agent; the brand was withdrawn in 2008 for commercial reasons. Compounded sermorelin is not an FDA-approved product.

FDA Category 2 (compounding restricted)

No

Available by prescription (US)

Yes, compounded on prescription by state-licensed pharmacies (no brand product since 2008)

Best-studied use

Pediatric growth hormone deficiency (the approved indication) and restoration of GH/IGF-1 levels in older adults (small trials)

Typical monthly cost (telehealth, 2026)

$150–$400 per month through telehealth, usually including clinician follow-up

What sermorelin is and how it works

Human growth hormone–releasing hormone (GHRH) is a 44-amino-acid peptide made in the hypothalamus. Sermorelin is the first 29 of those amino acids, which turns out to be the shortest fragment that keeps GHRH's full activity (Prakash & Goa 1999). Injected under the skin, it binds the GHRH receptor on the pituitary's somatotroph cells and triggers a pulse of growth hormone (GH), which in turn drives the liver to make insulin-like growth factor 1 (IGF-1), the hormone responsible for most of GH's effects on muscle, fat, bone and skin.

Two features explain why clinicians prefer it to injecting growth hormone directly:

1. The pulse is physiological. Sermorelin has a half-life of minutes, so it produces a short GH surge, ideally timed to the body's own largest pulse in the first hours of sleep. GH injections, by contrast, create a flat, sustained elevation the body never produces on its own.
2. Feedback stays intact. Rising IGF-1 and somatostatin still suppress the pituitary, which caps how much GH sermorelin can release. That is a safety feature, and also a ceiling on what it can do: a healthy, well-fed pituitary will not be pushed into acromegaly-range output.

The flip side is that sermorelin needs a working pituitary. In people whose GH deficiency comes from the pituitary itself (surgery, radiation, tumor), it does little, which is part of why the diagnostic test version existed: a poor GH response to sermorelin pointed to a pituitary problem, while a normal response pointed upstream, to the hypothalamus.

What the evidence actually shows

There is more human data on sermorelin than on almost any other peptide sold by wellness clinics. That is both the good news and the limit: the studies are real, but they are small, short, and mostly thirty years old. Here is the honest grading.

Sermorelin claims, graded by the evidence behind them

Claim	Grade	What the evidence shows	Sources
Raises growth hormone output in older adults	B	In 10 men aged ~68, GHRH(1-29) 1 mg twice daily for 14 days restored 24-hour GH and IGF-1 to the levels of men in their twenties; the 0.5 mg dose did not. In 11 men aged 64–76, 2 mg nightly for 6 weeks raised overnight GH output and peak amplitude.	Corpas 1992; Vittone 1997
Raises IGF-1	B	Inconsistent. IGF-1 rose at the 1 mg twice-daily dose (Corpas) and by ~28% with a closely related GHRH analog given nightly at 10 µg/kg for 16 weeks (Khorram), but did not change with 2 mg once nightly for 6 weeks (Vittone).	Corpas 1992; Khorram 1997; Vittone 1997
Treats growth hormone deficiency in children	A	The approved indication. Sermorelin 30 µg/kg subcutaneously at bedtime increased height velocity in prepubertal children with idiopathic GH deficiency, sustained over 12 months.	Prakash & Goa 1999
Improves strength or body composition in healthy older adults	C	Small, mixed signals: 2 of 6 strength measures and one endurance test improved after 6 weeks of nightly 2 mg GHRH(1-29), with no IGF-1 change. No adequately powered trial of body composition exists.	Vittone 1997
Improves sleep	C	GHRH itself increases slow-wave (deep) sleep in humans under some conditions, and the GHRH-analog trial in older adults collected sleep questionnaires. There is no sermorelin trial with objective sleep outcomes in the people it is marketed to.	Schüssler 2006; Khorram 1997
Supports immune function	C	In 19 adults aged 55–71, 16 weeks of a nightly GHRH analog increased some immune-cell markers (CD71+ lymphocytes, monocytes). Clinical relevance unknown.	Khorram 1997b
Reduces belly (visceral) fat	C	The strong visceral-fat data belong to tesamorelin, a different GHRH analog, in HIV-associated lipodystrophy (~15% visceral fat reduction over 26 weeks). There is no equivalent sermorelin trial.	Falutz 2007
Anti-aging, longevity, healthspan	D	No trial has measured aging outcomes. The closest evidence is for growth hormone itself in healthy elderly people: ~2 kg less fat and ~2 kg more lean mass, no functional benefit, and more edema, joint pain, carpal tunnel and glucose problems.	Liu 2007
Helps hypogonadal men on testosterone	C	A 2020 review concludes GH secretagogues plausibly complement testosterone for body composition, while noting that clinical data are largely lacking.	Sinha 2020

Three things stand out from that table.

First, the doses. Every positive adult result used 1–2 mg of GHRH(1-29) a day, or a weight-based dose equivalent to roughly 0.7–0.9 mg for an average adult. We will come back to this, because the compounded products most people are prescribed deliver a fraction of that.

Second, the outcomes. The trials measured hormones well and measured the things patients care about — strength, fat, sleep, recovery — only lightly. Raising GH and IGF-1 is a mechanism, not a result.

Third, the gap between sermorelin and "GHRH analog." The longest and best-designed adult trial (Khorram 1997, 16 weeks of treatment after a 4-week single-blind placebo period) used [Nle27]GHRH(1-29)-NH2, a version with one amino acid substitution that makes it more stable. Its results are supportive of sermorelin but not identical to it.

What you are promised versus what is documented

Marketing pages for sermorelin usually list the same benefits: deeper sleep, faster recovery, more lean muscle, less fat, better skin, more energy, "anti-aging." The evidence sorts those into three bins.

• Documented in humans: higher overnight GH output; higher IGF-1 at adequate doses; increased height velocity in GH-deficient children.
• Plausible but unproven in humans at wellness doses: deeper slow-wave sleep, modest strength gains, modest shifts in body composition, immune-marker changes.
• Not supported: longevity or healthspan extension, visceral-fat loss comparable to tesamorelin, skin or hair benefits, any effect on cognition.

That does not make sermorelin useless. For an adult with a documented low IGF-1 and symptoms consistent with low GH output, it is the most conservative tool a clinician has to nudge the axis upward while keeping feedback intact. It makes "sermorelin for longevity" a claim you should not pay for.

Sermorelin vs HGH, tesamorelin, and CJC-1295/ipamorelin

The practical ranking for most adults is tesamorelin for proven visceral-fat reduction (at a price), sermorelin for a prescribable, feedback-preserving GH nudge, and the CJC/ipamorelin combination as the one with the weakest evidence and the most legal exposure. Read the tesamorelin profile and the CJC-1295/ipamorelin profile for the detail.

Dosage: what was studied versus what clinics prescribe

The arithmetic is uncomfortable but important: a 300 mcg nightly dose is 3–7 times lower than the doses that produced the published hormone changes. Some clinicians argue that nightly timing, better injection technique and longer treatment make up the difference; others titrate upward based on IGF-1. Neither position has a trial behind it. If you are paying for sermorelin, ask your clinician what dose they expect to move your IGF-1 and when they will measure it.

Timing and technique

• Bedtime, empty stomach. The body's largest GH pulse comes in early slow-wave sleep, and food, glucose and insulin blunt GH release. Most clinicians advise injecting 30–60 minutes before sleep and at least two hours after the last meal.
• Subcutaneous, rotated sites. Abdomen (keeping 2 inches from the navel), thigh or upper arm, rotating to limit the injection-site reactions that are sermorelin's most common side effect. See how to inject peptides.
• "Five on, two off" and other cycling schedules are common in clinic protocols and have no study basis either way. They exist mainly to reduce cost and injection fatigue.

Reconstitution example

A common compounded vial is 6 mg of lyophilized sermorelin. Reconstituted with 3 mL of bacteriostatic water it gives 2 mg/mL, or 2,000 mcg/mL. A 300 mcg dose is then 0.15 mL, which reads as 15 units on a standard U-100 insulin syringe. Different pharmacies use different vial sizes and dilutions, so run your own numbers in the reconstitution calculator, and trust the label over the calculator if they disagree.

What a reasonable monitoring plan looks like

Baseline IGF-1, fasting glucose or HbA1c, and a basic metabolic panel; repeat IGF-1 and glucose at 8–12 weeks; then every 3–6 months. A clinician who prescribes sermorelin without ever measuring IGF-1 is prescribing by faith.

Side effects and who should not use it

Most common: injection-site redness, swelling or pain, in about 1 in 6 patients in the Geref pediatric program, which led 3 of 350 children to stop. Uncommon (each under 1 percent on the former label): facial flushing, headache, dizziness and hives; nausea appeared mainly with the intravenous diagnostic dose. Clinics also report a transient metallic taste, which has no published rate.

Less common: hyperactivity or sleep disturbance if dosed at the wrong time, hives or other hypersensitivity reactions, and antibodies against GHRH, which formed in a substantial share of children in the pediatric program (secondary reproductions of the withdrawn label describe anywhere from about a quarter to a large proportion), without an obvious loss of effect.

The risks that come from raising GH and IGF-1 have not been studied for sermorelin specifically, so the best available guide is the systematic review of growth hormone in healthy elderly people: more soft-tissue edema, joint pain, carpal tunnel syndrome and gynecomastia, and a higher rate of impaired fasting glucose and new diabetes (Liu 2007). Sermorelin's feedback-preserving mechanism should make these less likely at physiologic doses, but "should" is not data.

Do not use sermorelin, or use it only with a specialist's sign-off, if you have:

• an active cancer or a recent cancer history (GH/IGF-1 are growth signals);
• uncontrolled diabetes or diabetic retinopathy;
• untreated hypothyroidism or ongoing glucocorticoid treatment (both blunt the response, and both need managing first);
• a known pituitary disorder, acromegaly, or an intracranial mass;
• pregnancy or breastfeeding;
• a prior hypersensitivity reaction to sermorelin or GHRH.

Sermorelin is not an anabolic steroid and does not act on androgen receptors, but it is a banned substance in competitive sport under WADA's S2 category (peptide hormones and growth factors). Athletes subject to testing should treat it as prohibited.

Legal status in the United States

Sermorelin's regulatory story is unusual among wellness peptides, and it matters for how safely you can obtain it.

• It was an approved drug. Sermorelin acetate was approved by FDA in the late 1990s as Geref (for treating pediatric growth hormone deficiency) and Geref Diagnostic (for testing GH reserve). The manufacturer withdrew the brand from the US market in 2008. The withdrawal was commercial, not a safety recall.
• It is compounded, not approved. Today sermorelin reaches patients through 503A compounding pharmacies, which may prepare a medication for an individual patient on a valid prescription. A compounded drug is not reviewed or approved by FDA, and its potency and sterility depend on the pharmacy.
• It is not on FDA's Category 2 list. In 2023–2024 FDA placed a group of peptides commonly sold by wellness clinics — including BPC-157, CJC-1295, ipamorelin, TB-500, MOTS-c, epitalon, kisspeptin-10, AOD-9604, Selank, DSIP, Melanotan II and injectable GHK-Cu — in Category 2 of its 503A bulk-substances evaluation, meaning they may present significant safety risks and are not eligible for routine compounding (FDA Category 2). In April 2026 FDA took twelve of those peptides off the Category 2 list after their nominations were withdrawn, and in July 2026 its advisory committee recommended adding six of them (BPC-157, KPV, TB-500, MOTS-c, epitalon and semax) to the permitted list; as of October 2026 FDA has not completed the rulemaking, so none of them can be legally compounded yet. Ipamorelin and CJC-1295 went the other way: the committee voted against both in late 2024, and although FDA now lists them as nominated but withdrawn rather than in Category 2 (FDA categories 2026), neither can be compounded. Sermorelin was nominated to the 503A bulks list and was not placed in Category 2 (FDA 503A bulks list). That distinction is why a licensed pharmacy can still dispense sermorelin on prescription while the others have largely moved to the "research use only" gray market.
• State rules vary. Telehealth prescribing requires a clinician licensed in your state, and some states restrict which compounded products their pharmacies may ship. A legitimate provider will tell you which states they serve before taking your money.

Cost and how to get it prescribed

As of late 2026, US telehealth providers list compounded sermorelin at roughly $150–$400 per month, usually including the clinician visit and follow-up and sometimes a lab panel; local anti-aging clinics charge more. A 6 mg vial lasts about 20 nights at 300 mcg.

What a legitimate prescription path looks like:

1. A clinician licensed in your state reviews your history and labs, including a baseline IGF-1.
2. The pharmacy is named on the prescription and the shipment, and is a state-licensed 503A (or an FDA-registered 503B) facility.
3. You get follow-up: repeat IGF-1 and glucose, dose adjustment, and someone to message about side effects.
4. Nobody promises outcomes. A provider who guarantees fat loss, "reversed aging" or specific IGF-1 numbers is selling, not treating.

Red flags are the mirror image: no clinician contact, no labs, no pharmacy name, a shopping cart instead of a consultation, or sermorelin bundled with peptides that no licensed pharmacy may compound (BPC-157, CJC-1295, ipamorelin) as a "stack."

Sermorelin for women

Most sermorelin marketing is aimed at men, but the best adult trial enrolled slightly more women than men, and GH and IGF-1 rose in both sexes at the same weight-based dose (Khorram 1997). Women in perimenopause and menopause often ask about sermorelin for sleep and body composition; there is no sermorelin trial in that population, and hormone therapy has far stronger evidence for menopausal sleep disruption. If a clinician prescribes both, the same monitoring applies. Sermorelin should not be used in pregnancy or while breastfeeding. See peptides for women for the broader picture.

Bottom line

Sermorelin is the rare wellness peptide with an FDA approval history, real human trials and a prescription path through licensed pharmacies. What it reliably does is raise your own growth hormone output in a physiological pattern, with IGF-1 following at adequate doses. What it has not been shown to do is change how you age, melt visceral fat, or build muscle in a healthy adult; the trials that would answer those questions have not been run, and the doses most clinics use are well below the ones that were studied.

A reasonable use is a symptomatic adult with low IGF-1, prescribed by a clinician who measures the hormone before and after and who will stop if it does nothing. An unreasonable use is a subscription bought on the promise of longevity.

Frequently asked questions

+−Is sermorelin FDA approved?

Sermorelin was FDA-approved under the brand name Geref for diagnosing and treating growth hormone deficiency in children, and the brand was withdrawn from the market in 2008 for commercial reasons, not safety. Today sermorelin is available only as a compounded medication prepared by a state-licensed pharmacy on a clinician's prescription. Compounded sermorelin is not an FDA-approved product, and the adult wellness uses it is marketed for were never part of the approval.

+−What are the downsides of taking sermorelin?

The most common problem is an injection-site reaction (redness, swelling, pain), reported in about 1 in 6 patients in the original pediatric program; flushing, headache, dizziness and hives were each uncommon, and nausea was reported mainly with the intravenous diagnostic dose. Because sermorelin raises growth hormone and IGF-1, the theoretical long-term concerns are the same as for growth hormone itself: fluid retention, joint pain, carpal tunnel symptoms, reduced insulin sensitivity and, in people with an active cancer, stimulation of growth-signaling pathways. There are no long-term safety studies of sermorelin in healthy adults.

+−What will sermorelin do to your body?

Sermorelin signals the pituitary gland to release its own growth hormone in the normal pulsatile pattern, mainly during the first hours of sleep. In older adults, studied doses raised overnight growth hormone output and, in some trials, IGF-1. Whether that translates into meaningful changes in body composition, sleep quality or recovery is less clear: the trials were small, short, and reported modest or inconsistent results.

+−What should you not mix with sermorelin?

Glucocorticoids (prednisone and similar), untreated hypothyroidism, obesity and high blood sugar all blunt the growth hormone response to GHRH, so sermorelin tends to do less in those settings. Most clinicians advise injecting at bedtime on an empty stomach because food and insulin suppress GH release. Sermorelin has no documented dangerous drug interactions, but it should not be combined with other GH secretagogues or with growth hormone without a clinician managing the whole protocol.

+−Is sermorelin like Ozempic?

No. Ozempic (semaglutide) is a GLP-1 receptor agonist that lowers appetite and blood sugar; sermorelin is a GHRH analog that raises growth hormone. They act on different hormones, have different evidence bases and different side effects. Sermorelin is not a weight-loss drug, although some clinics prescribe it alongside GLP-1 medication to support lean mass during weight loss; there are no trials of that combination.

+−Does sermorelin need to be refrigerated?

Yes. Lyophilized (powder) vials are kept refrigerated at 2–8 °C, and once reconstituted with bacteriostatic water the vial stays refrigerated and should be used within the beyond-use date on your pharmacy label, typically two to four weeks. Do not freeze it.

+−How long does sermorelin take to work?

Growth hormone release rises from the first injection. Measurable IGF-1 changes, where they occur, appeared within about four weeks in the older-adult trials. Subjective effects such as deeper sleep are usually reported within the first weeks, while any change in body composition takes months and was modest in the studies. If IGF-1 has not moved after 8–12 weeks, the dose or the diagnosis deserves a second look.

+−Can women take sermorelin?

Yes. The longest GHRH-analog trial in older adults enrolled ten women and nine men aged 55–71, and GH and IGF-1 rose in both sexes. There is no sermorelin-specific data on menopause symptoms. It should not be used in pregnancy or while breastfeeding.

+−Sermorelin vs ipamorelin: which is better?

They work on different receptors: sermorelin on the GHRH receptor, ipamorelin on the ghrelin (GHS-R) receptor. Sermorelin has an FDA approval history and human trial data; ipamorelin has almost no human data in adults, and FDA has not permitted it for compounding: it flagged ipamorelin as a safety risk in 2023, and its advisory committee voted 12 to 0, with one abstention, against adding it to the permitted list in October 2024. For most people the practical answer is that sermorelin is the one a licensed clinician can prescribe from a licensed pharmacy.

+−Can I take sermorelin with testosterone?

Clinics commonly prescribe them together for men on testosterone therapy, and there is no documented interaction. The trials of growth hormone secretagogues in hypogonadal men are small, so the benefit of adding sermorelin to testosterone is plausible but unproven. Both should be managed by the same clinician with IGF-1, glucose and hematocrit monitored.

Sources

1. StudyCorpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992;75:530-5. (1992)
2. StudyVittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96. (1997)
3. StudyKhorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-9. (1997)
4. StudyKhorram O et al. Effects of [norleucine27]GHRH (1-29)-NH2 administration on the immune system of aging men and women. J Clin Endocrinol Metab 1997;82:3590-6. (1997)
5. ReviewPrakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999;12:139-57. (1999)
6. ReviewWalker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 2006;1:307-8. (2006)
7. ReviewLiu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-15. (2007)
8. ReviewSinha DK et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol 2020;9(Suppl 2):S149-59. (2020)
9. StudySchüssler P et al. Growth hormone-releasing hormone and corticotropin-releasing hormone enhance non-rapid-eye-movement sleep after sleep deprivation. Am J Physiol Endocrinol Metab 2006. (2006)
10. StudyFalutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-70. (2007)
11. RegulatoryFDA. Bulk drug substances used in compounding under section 503A of the FD&C Act.
12. RegulatoryFDA. Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list).
13. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)